Enasidenib, an IDH2 inhibitor, and ivosidenib, an IDH1 inhibitor, were approved in 2017 and 2019, respectively, for the treatment of patients with AML bearing IDH2 or IDH1 mutations. This evidence concerns the gene IDH2 and acute myeloid leukemia.